Results 251 to 260 of about 4,400 (309)

ET-3/ETBR Mediates Na<sup>+</sup>-Activated Immune Signaling and Kidney Lymphatic Dynamics. [PDF]

open access: yesCirc Res
Mutchler AL   +9 more
europepmc   +1 more source

Signaling Molecules and Diagnosis of Cognitive Disorders: Current State and Prospects. [PDF]

open access: yesInt J Mol Sci
Kvetnoy I   +8 more
europepmc   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ISEV2026 Abstract Book

open access: yes
Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Endothelins

New England Journal of Medicine, 1995
Ellis R Levin
exaly   +3 more sources

Endothelins in chronic liver disease

open access: yesScandinavian Journal of Clinical and Laboratory Investigation, 1996
Udgivelsesdato: 1996-OctThis review describes recent progress in the accumulation of knowledge about the endothelins (ETs), a family of vasoactive 21-amino acid polypeptides, in chronic liver disease.
Søren Møller, Jens H Henriksen
exaly   +1 more source

Endothelins

Blood Vessels, 2008
The endothelins (ETs) are a family of newly discovered peptides with potent vasoconstrictor properties. They were first discovered in cultured endothelial cells but ET expression has since been found in many other tissues such as brain and kidney. They are peptides with 21 amino acids formed by hydrolytic cleavage of a larger peptide, big ET.
E E, Anggård, R M, Botting, J R, Vane
openaire   +2 more sources

Endothelin

Hormone Research, 2008
Endothelin (ET) belongs to a family of 21 amino acid peptides comprising at least three isoforms in man. Originally identified as an endothelium-derived vasoconstrictive substance ET arises from a precursor peptide which is cleaved and released by a specific ET-converting enzyme.
P E, Chabrier, P, Braquet
openaire   +2 more sources

The endothelin system and endothelin receptor antagonists

Current Opinion in Nephrology & Hypertension, 2012
There is increasing evidence that endothelin receptor blockade and, in particular, ET(A) receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection.Recent clinical trials using ET(A) receptor blockade in treating proteinuria and chronic kidney disease as well as atherosclerosis show ...
Karin A M, Jandeleit-Dahm   +1 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy